SecSonar.com

XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

XTL Biopharmaceuticals Ltd. (XTLB) is a Biotechnology company based in IL with a market capitalization of $5.7M. Free cash flow was negative at -$1.7M. This page tracks XTLB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

IL · 10 employees · IPO Sep 1, 2005

Valuation

Valuation & price

$2.61 · as of May 17, 2026 · -68.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.04

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$8.20$5.13$2.06Jul 25Dec 25Jul 26Jul 7, 25$4.88Jul 9, 25$6.40Jul 11, 25$6.04Jul 15, 25$6.52Jul 17, 25$7.00Jul 21, 25$7.28Jul 23, 25$7.20Jul 25, 25$7.00Jul 29, 25$6.80Jul 31, 25$5.60Aug 4, 25$6.84Aug 6, 25$5.56Aug 11, 25$5.92Aug 13, 25$5.68Aug 15, 25$5.64Aug 19, 25$5.28Aug 21, 25$4.96Aug 25, 25$4.92Aug 27, 25$4.72Aug 29, 25$4.92Sep 3, 25$4.72Sep 5, 25$5.00Sep 9, 25$6.00Sep 11, 25$5.60Sep 16, 25$4.88Sep 18, 25$4.96Sep 22, 25$4.80Sep 24, 25$4.80Sep 26, 25$4.68Sep 30, 25$4.68Oct 2, 25$4.68Oct 6, 25$4.56Oct 8, 25$8.20Oct 10, 25$5.60Oct 14, 25$5.24Oct 16, 25$5.28Oct 21, 25$5.16Oct 23, 25$4.96Oct 27, 25$4.80Oct 29, 25$4.76Oct 31, 25$4.28Nov 4, 25$4.04Nov 6, 25$4.00Nov 10, 25$3.77Nov 12, 25$3.88Nov 14, 25$3.68Nov 18, 25$3.60Nov 20, 25$3.25Nov 25, 25$3.12Nov 28, 25$3.33Dec 2, 25$3.36Dec 4, 25$3.49Dec 8, 25$3.41Dec 10, 25$3.33Dec 12, 25$3.40Dec 16, 25$3.12Dec 18, 25$3.24Dec 22, 25$3.23Dec 24, 25$3.14Dec 29, 25$2.69Jan 2, 26$2.40Jan 6, 26$2.75Jan 8, 26$2.76Jan 12, 26$2.73Jan 14, 26$3.76Jan 16, 26$3.95Jan 21, 26$3.88Jan 23, 26$4.24Jan 27, 26$3.40Jan 29, 26$3.35Feb 2, 26$3.34Feb 4, 26$4.28Feb 9, 26$3.81Feb 11, 26$3.61Feb 13, 26$3.57Feb 18, 26$3.57Feb 20, 26$3.50Feb 24, 26$3.20Feb 26, 26$3.05Mar 2, 26$3.06Mar 4, 26$3.24Mar 6, 26$2.91Mar 10, 26$2.53Mar 12, 26$2.52Mar 17, 26$2.43Mar 19, 26$2.36Mar 23, 26$2.33Mar 25, 26$2.71Mar 27, 26$2.51Mar 31, 26$2.41Apr 2, 26$2.43Apr 7, 26$2.38Apr 9, 26$2.48Apr 13, 26$2.40Apr 15, 26$2.38Apr 17, 26$2.45Apr 22, 26$2.51Apr 24, 26$2.43Apr 28, 26$2.30Apr 30, 26$3.90May 4, 26$3.82May 6, 26$3.25May 8, 26$2.54May 12, 26$2.61May 14, 26$2.70May 18, 26$2.70May 20, 26$2.57May 22, 26$2.51May 28, 26$2.46Jun 1, 26$2.40Jun 3, 26$2.26Jun 5, 26$2.06Jun 9, 26$2.32Jun 11, 26$2.34Jun 15, 26$2.30Jun 17, 26$2.42Jun 22, 26$2.70Jun 24, 26$2.79Jun 26, 26$2.36Jul 2, 26$2.70
$2.0652-week range$8.20
Loading valuation history…

Fundamentals

Key fundamentals

$5.7M

Market cap

—

Revenue growth (YoY)

0.7%

Gross margin

-$1.7M

Free cash flow (USD)

-$1M

Net debt

Net cash position

23.5%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2015 → 2024

FY 2015$0.00FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$451.0K
$0$451K

Free cash flow by year

2015 → 2024

FY 2015$-1.9MFY 2016$-1.8MFY 2017$-1.1MFY 2018$-816.0KFY 2019$-910.0KFY 2020$-851.0KFY 2021$-1.0MFY 2022$-901.0KFY 2023$-707.0KFY 2024$-1.7M
-$1.9M-$1.7M

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 20-F filed Jun 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Annual report20-F FiledJun 30, 2026Filing
  • 6-K filingAcquisition CompletedJun 30, 2026Filing
  • Annual reportAnnual Report FiledJun 29, 2026Filing
  • 6-K filingExtraordinary General MeetingJun 23, 2026Filing
  • 6-K filingRegulatory UpdateMay 22, 2026Filing
  • 6-K filingExtraordinary General Meeting NoticeMay 15, 2026Filing
  • 6-K filingRegulatory UpdateMay 7, 2026Filing
  • 6-K filingShare Purchase AgreementApr 29, 2026Filing

Questions

Frequently asked questions

What is XTL Biopharmaceuticals Ltd.'s market cap?

XTL Biopharmaceuticals Ltd. (XTLB) has a market capitalization of $5.7M.

What is XTLB's P/E ratio?

A meaningful P/E ratio is not available for XTLB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is XTLB's price-to-book (P/B) ratio?

XTLB trades at 1.04 times book value per share.

Are insiders buying XTLB stock?

SEC Form 4 filings show no open-market insider buys at XTL Biopharmaceuticals Ltd. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

RADX

Radiopharm Theranostics Limited

$5.8M

NITO

N2OFF, Inc.

$5.5M

MLEC

Moolec Science S.A.

$5.5M

BCDA

BioCardia, Inc.

$5.5M

CELZ

Creative Medical Technology Holdings, Inc.

$5.9M

XBIO

Xenetic Biosciences, Inc.

$5.9M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.